AbbVie has finally claimed FDA approval for its advanced Parkinson's disease therapy Vyalev, 18 months after the US regulator turned it down with a request for more data.
Regeneron is the second pharma group to sign up for access to data from a remote study run by health technology firm Koneksa that is exploring the use of digital biomarkers to track patient
Dementia with Lewy bodies (DLB) may not be as well-known as other forms like Alzheimer’s, but is just as devastating, so the discovery that commonly used drugs may reduce the risk of the di
An artificial intelligence-powered blood test that may be able to predict Parkinson’s disease several years before symptoms start to develop could allow earlier treatment and help guide the
In a new white paper from the World Without Disease initiative, a 2024 update is provided of the current endeavours and developments that have occurred since inaugural discussions last year